Life Sciences Insight

J&J Strengthens Its Stronghold in Medtech

Johnson & Johnson’s medtech business saw a competitive growth rate of 6% in the first half of the year.

Johnson & Johnson has spent a lot of resources in recent years to refine its role in the medtech space through restructuringrebrandingdivestitures, and M&A. A look at the New Brunswick, NJ-based company’s most recent earnings report confirms that the company’s medtech unit is building momentum and increasing its competitiveness.

J&J CEO Joaquin Duato told analysts and investors during the second-quarter earnings call that the company currently has 11 medtech platforms that each delivered more than $1 billion in annual revenue, and that 10 of those platforms are maintaining or gaining market share. He also said Johnson & Johnson MedTech delivered 6% adjusted operational growth in the first half of 2022.

“Over the past several years, this acceleration in performance has been driven by the delivery of differentiated solutions as well as improved commercial execution. We expect this improvement to continue, enabled by our innovative pipeline as well as the potential for expansion into higher growth market segments,” Duato said. “…And based on the most recent results, we are gaining or holding share in nearly all of these.”

The focus of the unit is to continue strengthen its current strongholds, he said, and also accessing some high-growth market segments to accelerate growth. Duato also noted that, down the road, he continues to see M&A as an important source of building the pipeline and fortifying the current portfolio.

“My view is that we are already getting competitive growth rates in MedTech with 6% in the first half of the year. The growth rate in the second quarter has to be also put into perspective in the fact that the comparison with the second quarter of 2021 is a difficult one. MedTech grew 59% in the second quarter of 2021. And also there was some impact of the mobility restrictions in Asia Pacific,” Duato said.

Recent J&J MedTech pipeline milestones

  • In May, J&J’s Ethicon company received FDA 510(k) clearance for the Monarch surgical robotics platform to be used in endourological procedures. The company said the clearance makes Monarch the first multispecialty, flexible robotic solution for use in both bronchoscopy and urology.
  • Also in May, the company enrolled the first patient in its admIRE electrophysiology pulse field ablation study.
  • Earlier this year, J&J launched its Echelon 3000 stapler, a digitally enabled device backed by evidence that shows improvement in patient outcomes in the cerebrovascular space.
  • The company recently launched the Emboguard balloon catheter, which is designed to optimize the removal of blood clots in ischemic stroke.

“So, we feel optimistic about the combination of executing on our commercial priorities and at the same time, continue the good cadence of new product innovation that, that is going to take us to competitive growth as demonstrated by our 6% growth in the first half of the year,” Duato said.

SHARE
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn